GlassScriptPhysician profile
Brian Neal Walker
NPI 1144290032
$3,789.16
in general payments reported to CMS, 2019-2025
36 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.73 · 2020: $240 · 2021: $330 · 2022: $305 · 2023: $503 · 2024: $1,072 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.80 |
| Education | $238.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $490.82 | 2019-2025 | Keytruda, Lynparza |
| Abbvie INC. | $398.22 | 2021-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $347.05 | 2023-2025 | Opdivo, Opdualag |
| Sanofi-Aventis U.S. LLC | $324.90 | 2023-2025 | |
| Pfizer INC. | $313.85 | 2020-2025 | |
| Janssen Biotech, INC. | $307.70 | 2022-2025 | Darzalex, Talvey, Carvykti |
| Daiichi Sankyo INC. | $173.82 | 2024-2025 | Enhertu |
| Amgen INC. | $166.87 | 2020-2023 | Lumakras |
| Glaxosmithkline, LLC. | $142.10 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Celgene Corporation | $135.40 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Karyopharm Therapeutics INC. | $125.38 | 2020-2025 | Xpovio |
| Novartis Pharmaceuticals Corporation | $118.14 | 2021-2025 | |
| Intuitive Surgical, INC. | $90.59 | 2024 | |
| Genzyme Corporation | $67.65 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $48.97 | 2022-2023 | Imbruvica |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $46.57 | 2024-2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $46.50 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $43.61 | 2025 | Enhertu |
| Genentech USA, INC. | $41.38 | 2022-2025 | Venclexta |
| Exelixis INC. | $31.06 | 2025 | Cabometyx |
| Springworks Therapeutics, INC. | $30.56 | 2024 | Ogsiveo |
| Sobi, INC | $30.16 | 2025 | |
| Eisai INC. | $28.53 | 2021-2023 | |
| Gilead Sciences, INC. | $28.09 | 2021-2022 | |
| Lilly USA, LLC | $22.44 | 2025 | Verzenio, Jaypirca |
| Kyowa Kirin, INC. | $22.10 | 2024 | Poteligeo |
| Alexion Pharmaceuticals, INC. | $20.24 | 2024 | Ultomiris |
| Genmab U.S., INC. | $20.13 | 2025 | Epkinly |
| Incyte Corporation | $19.02 | 2025 | Jakafi |
| Deciphera Pharmaceuticals INC. | $18.06 | 2023 | Qinlock |
| Pharmacosmos Therapeutics INC. | $17.00 | 2025 | Monoferric |
| Puma Biotechnology, INC. | $16.87 | 2025 | |
| Cti Biopharma Corp. | $15.57 | 2023 | Vonjo |
| Kite Pharma, INC. | $13.76 | 2023 | Yescarta |
| Morphosys, US INC. | $13.54 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.